At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 353 enrolled
Drug / intervention
REGN5713 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating REGN5713, REGN5714, and 2 other interventions for Allergic Rhinitis and Conjunctivitis. Completed, enrolled 353 participants across 37 sites in 5 countries.
Detailed Summary
The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis, Conjunctivitis
CountriesBelgium, Canada, Denmark, Germany, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartJan 2021
Primary CompletionAug 2021
TodayJul 2026
First PostedJan 14, 2021
Enrollment StartJan 14, 2021
Primary CompletionAug 24, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.5 years ago
Interventions
REGN5713drug
Administered subcutaneously
REGN5714drug
Administered subcutaneously
REGN5715drug
Administered subcutaneously
Placebodrug
Placebo that replaces REGN5713-5714-5715